LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. LYVE1 may function in lymphatic hyaluronan transport. Additionally, LYVE1 has a role in tumor metastasis.
Rat (90% sequence homology).
This antibody recognizes LYVE1.
KLH-conjugated linear peptide corresponding to mouse LYVE1.
Research Sub Category
Not recommended to work in western blot using mouse liver lysate.
Anti-LYVE1 Antibody is an antibody against LYVE1 for use in IH.
Apoptosis & Cancer
Evaluated by Immunohistochemistry in ovarian cancer tissue.
Immunohistochemistry Analysis: 1:1,000 dilution of this antibody detected LYVE1 in ovarian cancer tissue.
~ 40 kDa
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Ovarian cancer tissue
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.